Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-Current Assets: 2015-2025

Historic Non-Current Assets for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $24.9 million.

  • Editas Medicine's Non-Current Assets fell 55.94% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year decrease of 55.94%. This contributed to the annual value of $52.3 million for FY2024, which is 66.98% down from last year.
  • Latest data reveals that Editas Medicine reported Non-Current Assets of $24.9 million as of Q3 2025, which was down 10.53% from $27.8 million recorded in Q2 2025.
  • Editas Medicine's 5-year Non-Current Assets high stood at $170.2 million for Q4 2021, and its period low was $24.9 million during Q3 2025.
  • For the 3-year period, Editas Medicine's Non-Current Assets averaged around $88.9 million, with its median value being $98.4 million (2024).
  • In the last 5 years, Editas Medicine's Non-Current Assets spiked by 255.45% in 2021 and then crashed by 71.78% in 2025.
  • Quarterly analysis of 5 years shows Editas Medicine's Non-Current Assets stood at $170.2 million in 2021, then declined by 7.41% to $157.6 million in 2022, then climbed by 0.48% to $158.3 million in 2023, then crashed by 66.98% to $52.3 million in 2024, then tumbled by 55.94% to $24.9 million in 2025.
  • Its Non-Current Assets stands at $24.9 million for Q3 2025, versus $27.8 million for Q2 2025 and $38.8 million for Q1 2025.